| No. | ANA (−fold) | AMA M2 (U/mL) | ASMA (−fold) | LKM-1 | IgG (mg/dL) | IgM (mg/dL) | AST (IU/L) | ALT (IU/L) />500 | PLT (× 104/μL) | Tx |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Neg | 156 | Neg | Neg | 2946 | 368 | 18 | 10/− | 17.2 | SOF/LDV |
| 2 | Neg | 16.2 | Neg | Neg | 1518 | 115 | 74 | 44/− | 9.2 | SOF/LDV |
| 3 | 80 | 10.8 | Neg | Neg | 1953 | 82 | 78 | 85/− | 17 | SOF/LDV |
| 4 | Neg | 141 | Neg | Neg | 1486 | 280 | 45 | 51/− | 19 | SOF/LDV |
| 5 | Neg | 218 | Neg | Neg | 1615 | 101 | 63 | 68/− | 13.8 | OMV/PTV/r |
| 6 | 160 | Neg | Neg | Neg | 1565 | 117 | 77 | 62/− | 9.3 | DCV/ASV |
| 7 | 80 | Neg | Neg | Neg | 2308 | 248 | 43 | 44/− | 20.2 | SOF/LDV |
| 8 | 160 | Neg | Neg | Neg | 1947 | 36 | 32 | 31/− | 9.4 | SOF/LDV |
| 9 | >1280 | Neg | Neg | Neg | 4304 | 127 | 107 | 61/− | 10.9 | SOF/LDV |
| 10 | Neg | Neg | Neg | Neg | 1636 | 229 | 88 | 96/+ | 8.3 | SOF/RBV |
| 11 | 640 | Neg | Neg | Neg | 2208 | 160 | 50 | 56/+ | 17.7 | SOF/RBV |
| 12 | 80 | Neg | Neg | 63 | 2465 | 86 | 84 | 115/− | 14.3 | SOF/RBV |
ANA, anti-nuclear antibody; AMA, anti-mitochondrial antibody; ASMA, anti-smooth muscle antibody; LKM-1, anti-liver/kidney microsome type 1 antibody; Ig, immunoglobulin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PLT, platelets; Tx, DAA treatment for HCV; Neg, negative; +/−, with or without experience; SOF, sofosbuvir; LDV, ledipasvir; OBV/PTV/r, ombitasvir/paritaprevir/ritonavir; DCV/ASV, daclatasvir/asunaprevir; RBV, ribavirin.